

## APPENDIX 1

Please amend claims 50-53, and 72-75 to read as follows:

50. (Amended) The composition of claim 48, wherein the monoclonal antibody or fragment thereof [is capable of binding] specifically binds to an antigen expressed by a cancer cell.

51. (Amended) The composition of claim 48, wherein the monoclonal antibody or fragment thereof [is capable of binding] specifically binds to a CD56 antigen.

52. (Amended) The composition of claim 48, wherein the monoclonal antibody [or fragment thereof] is humanized N901 or humanized C242 and wherein the fragment of said monoclonal antibody is a fragment of humanized N901 or humanized C242.

53. (Amended) The composition of claim 48, wherein the [monoclonal antibody or] fragment [thereof] of the monoclonal antibody is Fv, Fab, Fab' or F(ab')<sub>2</sub>.

72. (Amended) The kit of claim 70, wherein the monoclonal antibody or fragment thereof [is capable of binding] specifically binds to an antigen expressed by a cancer cell.

73. (Amended) The kit of claim 70, wherein the monoclonal antibody or fragment thereof [is capable of binding] specifically binds to a CD56 antigen.

74. (Amended) The kit of claim 70, wherein the monoclonal antibody [or fragment thereof] is humanized N901 or humanized C242 and wherein the fragment of said monoclonal antibody is a fragment of humanized N901 or humanized C242.

75. (Amended) The kit of claim 70, wherein the [monoclonal antibody or] fragment [thereof] of the monoclonal antibody is Fv, Fab, Fab' or F(ab')<sub>2</sub>.